Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of AC-262536 and RAD-140 — mechanism, side effects, legal status, and pricing.
AC-262536 is a non-peptide nonsteroidal selective androgen receptor modulator (SARM) with an azabicyclooctane naphthalene-carbonitrile structure. It acts as a partial AR agonist, showing tissue-selective anabolic effects in preclinical models. No human trials have been conducted, and it is not FDA-approved. SARMs are prohibited in athletic competition under WADA category S1.2.
RAD-140 (testolone) is a non-steroidal small-molecule selective androgen receptor modulator (SARM) — not a peptide — developed by Radius Health. It is NOT FDA-approved for any indication. Grey-market use for bodybuilding is associated with documented drug-induced liver injury (hepatotoxicity), testosterone suppression, and adverse cardiovascular effects. It is a WADA-prohibited substance. It is tracked in peptide-research spaces because of overlapping grey-market performance use.
AC-262536
RAD-140
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
AC-262536
RAD-140
No pricing data yet.
Check RAD-140 prices →No human data exist. All pharmacology derives from a single 2008 preclinical publication. In castrated male rats dosed chronically for two weeks, AC-262536 significantly increased levator ani muscle growth and suppressed elevated luteinizing hormone, while producing only weak effects on prostate and seminal vesicle weight compared to testosterone. The compound has also been included in validated analytical panels for SARM residue surveillance in bovine muscle tissue, reflecting its presence in food-safety monitoring rather than therapeutic development.
Miller et al. (2010, ACS Med Chem Lett) first described the design, synthesis, and preclinical characterization of RAD140 as a high-affinity tissue-selective AR agonist. Jayaraman et al. (2014, Endocrinology) demonstrated neuroprotection in cultured neurons and kainate-lesioned rats. LoRusso et al. (2022, Clinical Breast Cancer) reported the first-in-human Phase 1 dose-escalation in ER+/HER2- metastatic breast cancer (MTD 100 mg/day); efficacy was modest and hepatic AEs were frequent (AST 59%, ALT 46%, bilirubin 27%), and development did not progress to approval. Leung et al. (2022, Ochsner Journal) and subsequent case series document severe cholestatic drug-induced liver injury from grey-market RAD-140 use. Van Wagoner et al. (2017, JAMA) showed that only ~52% of internet-marketed SARM products contained the labeled compound, compounding grey-market risk. FDA has issued public warnings that SARMs are not safe for human consumption, and RAD-140 is banned by WADA. No FDA approval pathway is currently established.
Key references
AC-262536 and RAD-140 are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs